copper peptide ghk-cu injection Dosage and Protocol: The 30-Day Cycle ghk-cu injectable human clinical trial

Predrag Sikiric's research group at the University of Zagreb, Croatia, beginning in the early 1990s

Not every patient achieves the weight loss targets they are hoping for, and a meaningful proportion of patients even on maximum doses do not reach the 1520% body weight reduction that clinical guidelines increasingly use as a benchmark for meaningful metabolic benefit

Because the needle stays in the fatty layer, there is less chance of catching a nerve or a blood vessel than with a deeper injection, which is one reason some clinicians prefer it for maintenance dosing

Peptides are temperature-sensitive proteins that denature (lose their three-dimensional structure) when exposed to temperatures above 8C for extended periods

Alston CL, et al